NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.xbiotech.comXBiotech is expected to complete its Phase I/II clinical trial of XB2001, an anti-IL-1⍺ antibody, in combination with ONIVYDE and 5-FU/LV for advanced pancreatic cancer on June 10, 2025. The study, conducted in the US, evaluates safety, tolerability, and efficacy in approximately 69 patients. ONIVYDE (irinotecan liposome) and 5-FU/LV are standard chemotherapies for pancreatic cancer. XB2001 is being investigated as an adjunct to improve outcomes in metastatic disease.
trial completionXBiotech is expected to complete its Phase 2 clinical trial of Natrunix in combination with methotrexate for the treatment of moderate to severe rheumatoid arthritis on March 15, 2026. The randomized study will enroll approximately 108 subjects and assess the efficacy and safety of Natrunix, a monoclonal antibody, versus placebo, both in combination with methotrexate. The trial includes a double-blind treatment phase and an open-label extension. Natrunix is being developed as a potential anti-inflammatory therapy for autoimmune conditions.
trial completion